AHMAD ABBOUD

Dr. AHMAD ABBOUD

Medicine, Université Laval, Québec, Canada
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2023 in Sensors
Verified
Journal Article
Open access
PDF file
BDBenjamin Doré
Benjamin Doré
AGAlex Gaudreault
Alex Gaudreault
GEGauthier Everard
Gauthier Everard
JAJohannes Ayena
Johannes Ayena
AAAHMAD ABBOUD
AHMAD ABBOUD
Charles BatchoCharles Batcho
Charles Batcho
Context: This review aimed to synthesize the literature on the acceptability, feasibility, and effectiveness of immersive virtual technologies to promote physical exercise in older people. Method: We performed a literature review, based on four databases (PubMed, CINAHL, Embase, and Scopus; last search: 30 January 2023). Eligible studies had to use immersive technology with participants aged 60 years and over. The results regarding acceptability, feasibility, and effectiveness of immersive technology-based interventions in older people were extracted. The standardized mean differences were then computed using a random model effect. Results: In total, 54 relevant studies (1853 participants) were identified through search strategies. Concerning the acceptability, most participants reported a pleasant experience and a desire to use the technology again. The average increase in the pre/post Simulator Sickness Questionnaire score was 0.43 in healthy subjects and 3.23 in subjects with neurological disorders, demonstrating this technology’s feasibility. Regarding the effectiveness, our meta-analysis showed a positive effect of the use of virtual reality technology on balance (SMD = 1.05; 95% CI: 0.75–1.36; p < 0.001) and gait outcomes (SMD = 0.7; 95% CI: 0.14–0.80; p < 0.001). However, these results suffered from inconsistency and the number of trials dealing with these outcomes remains low, calling for further studies. Conclusions: Virtual reality seems to be well accepted by older people and its use with this population is feasible. However, more studies are needed to conclude its effectiveness in promoting exercise in older people.

6 June 2016 in arXiv
Verified
Preprint
Open access
PDF file
AAAHMAD ABBOUD
AHMAD ABBOUD
AYAbdel-Karim Yazbek
Abdel-Karim Yazbek
JCJean-Pierre Cances
Jean-Pierre Cances
VMVahid Meghdadi
Vahid Meghdadi
This paper deals with the improvement of energy efficiency in wireless sensor networks (WSN).Taking into consideration the power saving problem which is of crucial importance when the sensors are supplied by a limited power source, this paper proposes a method that optimizes as much as possible the transmission power of the sensors. Under the assumption of perfect channel between the Base Station (BS) and the Sensor Nodes (SN's) and with sufficient power resources at the BS, transferring the effort of transmission power to the BS will not be a peculiar issue. This paper proposes a method that reduces the transmitted data at the SN's and compensate this by requesting the variance of the measured value form predicted values. Furthermore, a request management algorithm (RMA) is developed to reduce the amount of requested data based on consecutive successive predictions. The result of this method reveals a major impact on reducing the transmission power at the SN's. Keywords: Wireless Sensor Networks, Data Reduction, Time Series Forecasting, Artificial Neural Networks.

14 May 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
ZDZeinab Dalloul
Zeinab Dalloul
AAAHMAD ABBOUD
AHMAD ABBOUD
IDIman Dalloul
Iman Dalloul
MAMahmoud Abdelsalam
Mahmoud Abdelsalam
Background Osimertinib is the standard first-line treatment for EGFR-mutant non-small cell-lung cancer (NSCLC) harboring common activating mutations, including exon 19 deletions and L858R. It is also active against tumors with acquired T790M-resistance. However, the EGFR L858R+T790M compound mutation where both variants co-occur within the same tumor may confer distinct drug-sensitivity profiles not predicted by either mutation alone. Limited data exist on comparative treatment outcomes in this rare genotype.Methods Using the MSK-CHORD clinicogenomic dataset (n=24,950), we identified patients with concurrent EGFR L858R and T790M mutations receiving erlotinib (Erlo) or osimertinib (Osi) monotherapy. Real-world progression-free survival (rwPFS) per treatment line was calculated using a strict definition requiring confirmed radiological progression events (rwPFS-strict), excluding lines with null endpoint data. Kaplan-Meier analysis, log-rank testing, Cox proportional hazards regression, and cross-cohort heterogeneity testing (Cochran's Q statistic) were performed. Two control cohorts L858R-only (n=372) and T790M-only (n=76) were analyzed in parallel to assess mutation-context specificity of treatment response.Results Thirty-one patients with EGFR L858R+T790M were identified; 21 contributed evaluable monotherapy lines, yielding 23 Erlo and 15 Osi treatment lines (14 unique patients per treatment group, 7 contributing to both). Median rwPFS numerically favored Erlo over Osi (7.10 vs 5.32 months; HR 1.29, 95% CI 0.66–2.52; log-rank p=0.46). This directional trend was reversed in the L858R-only control cohort, where Osi demonstrated significant superiority (9.03 vs 5.75 months; HR 0.70, 95% CI 0.55–0.89; p=0.003). The T790M-only cohort showed no significant difference (HR 1.32, p=0.12). An exploratory post-hoc heterogeneity test confirmed a significant cross-cohort interaction (Q=9.94, df=2, p=0.007).Conclusions The expected osimertinib advantage was absent in L858R+T790M compound-mutant NSCLC. The opposing hazard ratio directions across mutation contexts (HR 1.29 vs 0.70), with a significant exploratory cross-cohort interaction (p=0.007), suggest that the EGFR L858R+T790M compound mutation may represent a pharmacologically distinct entity with differential TKI sensitivity. These hypothesis-generating findings warrant prospective validation.


30 April 2016 in arXiv
Verified
Preprint
Open access
PDF file
AAAHMAD ABBOUD
AHMAD ABBOUD
JCJean-Pierre Cances
Jean-Pierre Cances
AJAli H. Jaber
Ali H. Jaber
VMVahid Meghdadi
Vahid Meghdadi
Massive MIMO brings both motivations and challenges to develop the 5th generation Mobile wireless technology. The promising number of users and the high bitrate offered per unit area are challenged by uplink pilot contamination due to pilot reuse and a limited number of orthogonal pilot sequences. This paper proposes a solution to mitigate uplink pilot contamination in an indoor scenario where multi-cell share the same pool of pilot sequences, that are supposed to be less than the number of users. This can be done by reducing uplink pilots using Channel State Information (CSI) prediction. The proposed method is based on machine learning approach, where a quantized version of Channel State Information (QCSI) is learned during estimation session and stored at the Base Station (BS) to be exploited for future CSI prediction. The learned QCSI are represented by a weighted directed graph, which is responsible to monitor and predict the CSI of User Terminals (UTs) in the local cell. We introduce an online learning algorithm to create and update this graph which we call CSI map. Simulation results show an increase in the downlink sum-rate and a significant feedback reduction.